NHF’s Health Care Provider Webinar: Current Research & Future Approaches to Eradicating Inhibitors to Hemophilia
Inhibitors continue to be the predominant complication facing bleeding disorder clinicians, affected hemophilia patients and their families. The development of an inhibitor, particularly one that goes unabated for a prolonged period, will have significant negative impacts on overall health and quality of life. In addition, the considerable economic burdens associated with inhibitors is well documented. In response, the Inhibitor Prevention and Eradication Working Group conceived the “Current Research and Future Approaches to Eradicating Inhibitors in Hemophilia” webinar.
Presented by five providers with vast experience in bleeding disorders clinical care and research, the activity includes a description of the basic science behind the development of inhibitor antibodies to infused factor, associated complications of un-tolerated inhibitors and barriers to effective research. The second half of the webinar presents a way forward with a comprehensive and practical look at surveillance, scientific investigation and clinical studies, with an emphasis on a symbiotic approach to future efforts by healthcare providers, patients, industry, scientists and governmental agencies.
This webinar is jointly provided by the Postgraduate Institute for Medicine and the National Hemophilia Foundation.
To register, view the webinar and apply/receive continuing medical education (CME) or continuing nursing education (CNE) credits visit www.cmeuniversity.com/course/disclaimer/116285
Donna DiMichele, MD
Deputy Director, Division of Blood Diseases & Resources
National Heart, Lung and Blood Institute (NHLBI)
National Institutes of Health
Vanessa R. Byams, MPH
Acting Team Lead, Epidemiology and Surveillance Branch, Division of Blood Disorders
National Center on Birth Defects and Developmental Disabilities (NCBDDD)
Centers for Disease Control and Prevention
Roshni Kulkarni, MD
Professor Emerita of Pediatric Hematology/Oncology
Department of Pediatrics and Human Development
Director, Center for Bleeding and Clotting Disorders
Michigan State University
Margaret V. Ragni, MD, MPH
Professor of Medicine and Clinical Translational Science
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh Medical Center
Director, Hemophilia Center of Western PA
Shannon Carpenter, MD, MS
Professor of Pediatrics, University of Missouri–Kansas City School of Medicine
Director, Kansas City Regional Hemophilia Treatment Center
Children’s Mercy Hospital
Support for the webinar has been made possible through a cooperative agreement with the Centers for Disease Control and Prevention. The Inhibitor Prevention and Eradication Working Group is a working group of National Hemophilia Foundation’s Medical Scientific Advisory Council.
This educational activity was supported by a Cooperative Agreement, number NU27DD001154-04, funded by the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services. This activity is not supported by grants from any commercial entities.